October 2005 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

October 2005

Pharmaceutical Technology


GUIDANCE

New Impurities Guidance May Speed Generic Approvals

The US Food and Drug Administration (Rockville, MD, http://www.fda.gov/) released a new draft guidance that may speed generic approvals. The guidance, ANDAs: Impurities in Drug Products, describes the degradation-product information that generic drug manufacturers should include in their abbreviated new drug applications (ANDAs). This clarification, FDA officials say, will help companies submit the correct information, thus increasing the likelihood that their generic drugs will be approved, and approved more quickly.

"Deficiencies related to impurity specifications probably occur more often than any other deficiency in applications we see," says Gary Buehler, director of FDA"s Office of Generic Drugs (OGD). Those deficiencies result in a lot of "back-and-forth" discussions, Buehler says, between the agency and the sponsor company. Such dialogue means a longer review—often months longer—and delayed approval.

Buehler says that the new guidance will help reduce those discussions. "Our intention in putting out this guidance is to provide more predictability to the generic industry as to how they should prepare their applications," he says.

The draft guidance helps manufacturers understand which degradation products they should list in their ANDAs, how to set acceptance criteria, and what thresholds and procedures to apply when qualifying degradation products. The new guidance applies to generic drugs the guidelines established in the International Conference on Harmonization's Nov. 2003 guidance, Q3B(R) Impurities in Drug Products. "We want to make sure the policy for generic drugs is the same as [the policy for] innovator drugs," says Lawrence Yu, director for science at OGD.

Buehler says the guidance will also help ensure consistency among the 11 teams in OGD. "Because we hadn't clearly spelled out our policies with respect to impurities, we had difficulty sometimes with the interpretation of [those impurities] from division to division," he explains. "This gives [manufacturers] a clearer idea of what we would expect and also gives our own reviewers a clearer idea of what the office expects with respect to evaluating applications."

In some areas, the new guidance sets stricter standards for generic manufacturers, because some Q3B(R) thresholds are lower than the standards set in United States Pharmacopeia monographs, particularly for unspecified and unknown impurities. Nonetheless, Buehler and Yu don't expect a lot of industry comments on the draft. "The Office of Generic Drugs has been communicating with stakeholders and industry, so I think the industry will understand the approach and welcome a clear policy for impurities in generic drugs," says Yu.

–Laura Bush

MANUFACTURING

Improving Manufacturing Science Is Key, According to CDER Report

The FDA's Center for Drug Evaluation and Research (CDER, http://www.fda.gov/cder/, Rockville, MD) issued its 2004 report to the nation, citing the center's key initiatives: improving the science of drug manufacturing, streamlining the path for developing new drugs, and improving methods for identifying and analyzing drug safety issues.

The report says that the center's overhaul of the pharmaceutical good manufacturing practices "encourages manufacturers to modernize their methods, equipment, and facilities to eliminate both production inefficiencies and undue risks for consumers." It also says the risk-based approach to inspections makes "better use of limited resources."

The 66-page report, Improving Public Health through Human Drugs, says CDER developed initiatives to improve drug safety, protect against bioterrorism, and accelerate drug development while maintaining its performance in reviewing new drugs and overseeing the safety of marketed drugs. During 2004, CDER approved 119 new medicines and 380 generic versions of existing drugs, and evaluated more than 400,000 reports of adverse drug events, including more than 20,000 submitted directly by individuals.

–Laura Bush


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here